Here are three things to know.
- Tremfya is the only approved biologic drug that targets a specific protein secreted by cells that plays a main role in plaque psoriasis.
- Psoriasis patients receive Tremfya as an injection every eight weeks, with a dose administered at the first and fourth week to start.
- In a recent clinical trial, more than 7 out of 10 patients taking Tremfya had 90 percent clearer skin at week 24, compared to 4 out of 10 patients taking AbbVie’s rival drug Humira.
More articles on supply chain:
7 must-reads for supply chain leaders this week
Amgen leukemia drug earns full FDA approval after successful clinical trial
House passes FDA user fee reauthorization bill
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
